Phio Pharmaceuticals director Bradford Patricia A. bought 12,000 shares at $1.03 per share. The purchase matters to investors because her resulting holding stood at 57,651 shares, with the transaction representing about 20.8% of that post-purchase position.
Key Highlights
- The transaction occurred on Sep. 15 under transaction code P.
- Bradford Patricia A. held 57,651 shares after the purchase.
- Director Bradford Patricia A. purchased 12,000 shares of Phio Pharmaceuticals Corp. at $1.03 per share.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) recorded a 12,000-share purchase by director Bradford Patricia A. at $1.03 per share.
Purchase Details and Transaction Code
The stated price was $1.03 per share. Transaction code P marks the entry as a purchase within the transaction classification. Phio Pharmaceuticals Corp. is the named company associated with the shares.
Resulting Insider Ownership
The percentage is tied specifically to her post-transaction holding, while the 57,651 figure describes the shares owned after the purchase.
FAQs
Q: How many Phio Pharmaceuticals shares did Bradford Patricia A. buy?
A: The filing states that Bradford Patricia A. bought 12,000 shares of Phio Pharmaceuticals Corp. The reported purchase price was $1.03 per share.
Q: What was Bradford Patricia A.’s resulting PHIO share holding?
A: Bradford Patricia A. owned 57,651 Phio Pharmaceuticals shares after the transaction. She is identified as a director of the company.
Q: When did the Phio Pharmaceuticals insider purchase occur?
A: The article does not state when the Phio Pharmaceuticals insider purchase occurred. It identifies the transaction with code P, marking it as a purchase.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.